Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12143361 | 0.89 | APLNR (0.42) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL14258502 | 0.89 | PLK1 (0.35) | ADORA1PLK1APLNRCA1CA2 | |
| SCHEMBL13014750 | 0.87 | APLNR (0.37) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL2743023 | 0.87 | APLNR (0.37) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL15757814 | 0.87 | ADORA1 (0.38) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL23818338 | 0.87 | TDP1 (0.43) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL29467663 | 0.87 | MEN1 (0.44) | ADORA1PLK1CA1CA2MEN1 | |
| SCHEMBL14258522 | 0.84 | PLK1 (0.34) | ADORA1PLK1APLNRCA1CA2 | |
| SCHEMBL17655693 | 0.84 | APLNR (0.38) | ADORA1APLNRCA1CA2MEN1 | |
| SCHEMBL14679532 | 0.84 | APLNR (0.38) | ADORA1APLNRCA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080063701-A1 | Vector | IV VEC LIMITED (GB) | 2008-03-13 | — | — | US | disclosed |
| US-20080063701-A1 | Vector | IV VEC LIMITED (GB) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063701-A1 | Vector | LPCAT1, HDLBP, AGO2 | ADORA1 3943/4885PLK1 1082/4885APLNR 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.